BioNxt Solutions Targets Oral GLP-1 Market with New Drug Delivery Platform

BioNxt Solutions has unveiled a strategic pivot designed to position the company at the forefront of one of the pharmaceutical sector’s most dynamic growth areas. The new focus is on developing a scalable platform for the sublingual delivery of GLP-1 agonist drugs, the blockbuster class of therapeutics that includes treatments like Ozempic and Wegovy.

A Multi-Billion Dollar Opportunity

The market potential driving this shift is substantial. According to Fortune Business Insights, the global GLP-1 market reached approximately $63 billion in 2025 and is projected to expand to over $254 billion by 2034, representing a compound annual growth rate of nearly 17 percent. BioNxt aims to capture a segment of this market by moving away from injectable formats.

Initial Focus on Semaglutide

The company’s first development target is semaglutide, the highest-selling GLP-1 drug with annual revenues exceeding $29 billion in 2024 alone. The goal is to formulate this active ingredient into an oral dissolvable film (ODF) for administration under the tongue, thereby eliminating the need for injections.

Technical groundwork for this approach was established through earlier preclinical work by BioNxt’s German subsidiary, Vektor Pharma TF GmbH. Initial prototypes demonstrated promising characteristics, including rapid disintegration, uniform film quality, and good processability. However, the program remains in an early phase. Formulation work is ongoing, and critical parameters like bioavailability and release profiles still require validation. BioNxt is targeting the second half of 2026 to manufacture an Investigational Medicinal Product (IMP) for an initial clinical pilot study.

Should investors sell immediately? Or is it worth buying Bionxt Solutions?

Building a Broader Technology Platform

The long-term ambition extends beyond a single product. Management is evaluating whether its ODF technology can be applied to other GLP-1 compounds, such as tirzepatide and liraglutide. The company intends to generate new intellectual property from this platform development, covering formulations, carrier systems, and peptide delivery mechanisms.

Strengthening the Intellectual Property Foundation

Alongside the new GLP-1 initiative, BioNxt continues to fortify its existing patent portfolio. For its multiple sclerosis candidate, BNT23001, the company has initiated an accelerated examination procedure with the United States Patent and Trademark Office (USPTO), which is expected to conclude within nine to twelve months. National phase applications are also proceeding in Canada, Japan, Australia, and New Zealand—collectively representing a potential patient population of nearly one billion.

Share Price Context

BioNxt’s shares have retreated significantly from their 52-week high of €0.65, reached in August 2025, and currently trade around €0.30. Whether the new strategic direction can provide support for the share price will likely depend on the company’s ability to swiftly complete the necessary validation steps for its semaglutide program and provide concrete evidence of progress toward clinical trials.